Egypt’s pharmaceutical exports hit $1.3 billion as ‘Medicine City’ fuels expansion

This Video Is Trending Right Now →

Keypoints

• Egypt recorded $1.3 billion in pharmaceutical exports in 2025, a significant jump from $1.079 billion in 2024.
• The Egyptian Drug Authority (EDA) targets $1.6 billion to $1.7 billion for the 2026 fiscal year.
• A long-term national goal is set to reach $3 billion in annual medical industry exports by 2030.
• Growth is driven by Gypto Pharma (Medicine City), a 180,000-square-meter hub designed for regional leadership.
• Egypt now operates the largest pharmaceutical manufacturing base in the MENA region, covering nearly 30% of the market.

Main Story

Egypt is rapidly transforming into a regional powerhouse for life sciences. On Tuesday, April 21, 2026, data from the Egyptian Drug Authority revealed that the nation’s pharmaceutical exports climbed to approximately $1.3 billion over the past year.

This 20% year-on-year growth underscores Cairo’s strategic push to reduce reliance on imports and capture a larger share of the African and Middle Eastern markets.

The cornerstone of this expansion is Gypto Pharma, also known as “Medicine City.” Inaugurated to ensure national drug security, the facility now hosts 160 production lines and maintains partnerships with global giants like Abbott, Sanofi, and AstraZeneca.

By localizing the production of high-value segments—including oncology drugs and vaccines—Egypt is moving beyond simple generics into complex biotechnology. This industrial maturity allowed medical imports to drop by 18.5% in 2025, signaling a successful shift toward self-sufficiency.

The Issues

The primary challenge is the API-dependency hurdle; while Egypt manufactures 91% of its domestic needs, nearly 75% of the raw materials (Active Pharmaceutical Ingredients) are still imported from abroad. Authorities must solve the problem of regulatory-compliance friction

, as 35% of local manufacturers still struggle to meet the stringent international Good Manufacturing Practices (GMP) required for European and U.S. exports. Furthermore, there is a production-cost risk ; rising energy prices and global supply chain disruptions are expected to increase manufacturing costs by 15% in 2026. To succeed, the government must incentivize the domestic production of raw materials to stabilize profit margins and maintain competitive pricing in emerging markets.

What’s Being Said

• “NISSRAMP and other data tools are redefining how we manage our natural and industrial resources,” stated sector analysts, echoing the RMRDC’s data-driven approach.
• Health Ministry officials emphasized that the “Vaccine City” project alone aims to export products to over 60 countries by 2030.

What’s Next

• Egypt is expected to finalize the infrastructure for its 115,000-square-meter Vaccine City by the end of 2026, focusing on Hepatitis B and influenza vaccines.
• A new roadmap for the localization of oncology drugs is anticipated to reduce annual spending on cancer treatment imports by $500 million.
• The Egyptian Drug Authority will likely expand its Electronic Services Platform to streamline export licensing for the 1,200 companies currently operating under toll manufacturing.
• Trade missions to Sudan and sub-Saharan Africa are planned for later this year to secure long-term supply contracts for Egyptian-made medical supplies.

Bottom Line

Egypt’s $3 billion target for 2030 is no longer a distant dream but a visible horizon. By combining massive infrastructure like Medicine City with aggressive localization policies, Egypt is positioning its pharmaceutical sector as a vital engine for both foreign exchange and regional health security.